Frontiers in Oncology | Cancer Immunity and Immunotherapy

Original Research

Published on 17 Dec 2024

The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma

in Cancer Immunity and Immunotherapy

Yuyan Xie
Hao Sun
Liying Shan
Xin Ma
Qingyu Sun
Fang Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1454709

1,006 views

Systematic Review

Published on 12 Dec 2024

Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis

in Cancer Immunity and Immunotherapy

Jiahui Cao
Xinyao Ding
Jianan Ji
Lin Zhang
Chengyan Luo

Frontiers in Oncology

doi 10.3389/fonc.2024.1475502

1,637 views

General Commentary

Published on 12 Dec 2024

General commentary: GQIcombi application to subdue glioma via differentiation therapy

in Cancer Immunity and Immunotherapy

BinBin Yuan
Hui Gong

Frontiers in Oncology

doi 10.3389/fonc.2024.1466102

586 views

Systematic Review

Published on 11 Dec 2024

Efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma: a network meta-analysis of randomized controlled trials

in Cancer Immunity and Immunotherapy

Weiming Liang
Shibo Huang
Yanping Huang
Miaoyan Huang
Chunyan Li
Yiwen Liang
Li Pang

Frontiers in Oncology

doi 10.3389/fonc.2024.1453338

1,222 views

Original Research

Published on 05 Dec 2024

Association of the SNPs in CCL2 and CXCL12 genes with the susceptibility to breast cancer: a case-control study in China

in Cancer Immunity and Immunotherapy

Duanchong Zhao
Xingxing Yu
Hongli Huang
Shuqing Zou
Pingxiu Zhu
Yuxiang Lin
Mengjie Song
Fangmeng Fu
Haomin Yang

Frontiers in Oncology

doi 10.3389/fonc.2024.1475979

951 views

Review

Published on 02 Dec 2024

Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors

in Cancer Immunity and Immunotherapy

Pan Cheng
Jichen He
Pingping Cheng
Kaixia Chen
Guangyu Zhao

Frontiers in Oncology

doi 10.3389/fonc.2024.1468569

1,204 views

Correction

Published on 02 Dec 2024

Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

in Cancer Immunity and Immunotherapy

Mi Meng
Bo Yu
Jie Luo
Yuju Bai
Lin Li
Shicheng Chen
Sisi He
Hu Ma

Frontiers in Oncology

doi 10.3389/fonc.2024.1516024

420 views

Case Report

Published on 27 Nov 2024

Abscopal effect-induced spontaneous regression of distant metastases in malignant mesenchymal tumor: a case report

in Cancer Immunity and Immunotherapy

Meltem Kirli Bolukbas
Cemile Ozdemir
Esengul Kocak Uzel

Frontiers in Oncology

doi 10.3389/fonc.2024.1475129

594 views

Case Report

Published on 26 Nov 2024

Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review

in Cancer Immunity and Immunotherapy

Yinfang Gu
Lilan Yi
Xiaofang Zou
Longhua Guo
Guowu Wu
Jingjing Zhao

Frontiers in Oncology

doi 10.3389/fonc.2024.1442605

1,161 views
1 citation

Review

Published on 25 Nov 2024

Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy

in Cancer Immunity and Immunotherapy

Xiangyu Yin
Yunjie Song
Wanglong Deng
Neil Blake
Xinghong Luo
Jia Meng

Frontiers in Oncology

doi 10.3389/fonc.2024.1483454

1,977 views
2 citations

Original Research

Published on 25 Nov 2024

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching

in Cancer Immunity and Immunotherapy

Zeyang Wang
Bingnan Ren
Haotian Yang
Xuejia Qiu
Yin Wu
Chaojun Xue
Yue Zhao
Xiao Li
Ze Yu
Jinyuan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1446950

1,019 views

Original Research

Published on 25 Nov 2024

Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy

in Cancer Immunity and Immunotherapy

Anna Rudzińska
Pola Juchaniuk
Jakub Oberda
Kamila Krukowska
Sylwia Krzyśkowska
Eliza Kuchta
Anna Rodzajewska
Mariola Janiszewska
Katarzyna Szklener
Katarzyna Machulska-Ciuraj

Frontiers in Oncology

doi 10.3389/fonc.2024.1459608

952 views

Original Research

Published on 20 Nov 2024

Evening cortisol levels are prognostic for progression-free survival in a prospective pilot study of head and neck cancer patients

in Cancer Immunity and Immunotherapy

Elizabeth Cash
Isak Beck
Brooks Harbison
Christy Albert
Sandra E. Sephton

Frontiers in Oncology

doi 10.3389/fonc.2024.1436996

1,514 views

Review

Published on 19 Nov 2024

Progress on angiogenic and antiangiogenic agents in the tumor microenvironment

in Cancer Immunity and Immunotherapy

Jian Xu

Frontiers in Oncology

doi 10.3389/fonc.2024.1491099

1,564 views
1 citation

Editorial

Published on 19 Nov 2024

Editorial: Cell death in cancer immunology

in Cancer Immunity and Immunotherapy

Laura Mondragón
Shensi Shen
Laura Senovilla

Frontiers in Oncology

doi 10.3389/fonc.2024.1504738

795 views

Original Research

Published on 12 Nov 2024

Characterization of the T-cell receptor repertoire associated with lymph node metastasis in colorectal cancer

in Cancer Immunity and Immunotherapy

Ya’nan Zhen
Hong Wang
Runze Jiang
Fang Wang
Cunbao Chen
Zhongfa Xu
Ruixue Xiao

Frontiers in Oncology

doi 10.3389/fonc.2024.1354533

834 views
2 citations